Company news

NeuroOne Medical Technologies Corporation news in 2025

NeuroOne Medical Technologies Corporation's news releases, calls and decks from 2025, newest first.

View company

NeuroOne(R) Appoints Jason Mills to the Board of Directors

December 22, 2025

NeuroOne Reports Strong Fourth Quarter Fiscal 2025 Financial Results With Product Revenue Growth of 907% to $2.7 Million and 55.8% Gross Margin & Total Revenue Growth of 163% to $9.1 Million for Fiscal Year 2025

December 17, 2025

NeuroOne(R) to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Wednesday, December 17th at 8: 30 a.m. Eastern Time

December 11, 2025

NeuroOne(R) Announces Initial Successful Cases Completed With OneRF(R) Trigeminal Nerve Ablation System at the University Hospitals in Cleveland

December 9, 2025

NeuroOne(R) Announces Upcoming Industry Conference Participation

November 19, 2025

NeuroOne(R) Receives 180-Day Extension From Nasdaq to Regain Minimum Bid Price Compliance

November 5, 2025

NeuroOne Promotes Emily Johns to Chief Administrative Officer

October 16, 2025

NeuroOne(R) Bolsters Patent Portfolio With Recent Decisions From Both the U.S. Patent & Trademark Office and European Patent Office

October 14, 2025

NeuroOne Announces Preliminary Unaudited Product Revenue Growth of 163% to Record $9.1 Million, Invitation to Join Virtual Investor Webinar Tomorrow at 8: 30 am EST

October 6, 2025

NeuroOne(R) Announces Virtual Investor Webinar on October 7, 2025 at 8: 30 a.m. EST

September 29, 2025

NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025

September 8, 2025

NeuroOne Receives FDA 510(k) Clearance for OneRF Trigeminal Nerve Ablation System to Treat Facial Pain

August 19, 2025

NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

August 18, 2025

NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%

August 14, 2025

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8: 30 a.m. Eastern Time - Update

July 31, 2025

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8: 30 a.m. Eastern Time

July 31, 2025

NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office

July 23, 2025

NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System

June 23, 2025

NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

June 3, 2025

NeuroOne to Attend MedInvest’s MedTech, AI & Digital Health Conference on June 3-4, 2025

May 29, 2025

NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%

May 13, 2025

NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor

May 12, 2025

NeuroOne Medical Announces Participation in The D. Boral Capital Inaugural Global Conference

May 5, 2025

NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8: 30 a.m. Eastern Time

May 1, 2025

NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

April 23, 2025

NeuroOne® Issues Letter to Shareholders

April 16, 2025

NeuroOne® OneRF® Technology Success Story Featured on Fox News

April 14, 2025

NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock

April 4, 2025

NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

April 3, 2025

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace - Update

March 18, 2025

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace

March 18, 2025

NeuroOne CEO Joins Today’s Marketplace To Discuss The Latest Treatments for Epilepsy

March 18, 2025

NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

March 11, 2025

NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

March 5, 2025

NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update

February 11, 2025

NeuroOne® to Report First Quarter Fiscal Year 2025 Financial Results on Wednesday, February 12 at 8: 30 a.m. Eastern Time

February 4, 2025

NeuroOne® Regains Compliance with Nasdaq Listing Requirements

February 3, 2025

NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million

January 9, 2025

NeuroOne® Announces Change of Virtual Investor Webinar to Friday, January 10, 2024

January 5, 2025

NeuroOne® Announces Virtual Investor Webinar on January 9, 2025 at 11: 00 a.m. EST

January 2, 2025

Calls in 2025

Decks in 2025